News | November 02, 2008

ACIST, Nova to Co-Distribute Creatinine Meter

November 3, 2008 - ACIST Medical Systems Inc. (a Bracco Group company), signed a distribution agreement for the StatSensor Creatinine Meter with Nova Biomedical, in which the ACIST and Nova teams will co-exclusively market and distribute the StatSensor Creatinine Meter into the medical fields of radiology and cardiology within North America.

Within this new distribution structure, both ACIST and Nova will focus on providing its customers with continuity for the StatSensor solution from point of care deployment in imaging modalities where iodine- and gadolinium-derived intravenous contrast agents are administered, to platform management and its connectivity into the clinical laboratory.

ACIST will continue to support customers who have previously purchased the StatSensor Creatinine Meter under the E-Z-Chem brand name from E-Z-EM Inc. prior to the acquisition of certain assets by ACIST Medical Systems.

The StatSensor Creatinine device measures a patient's blood creatinine level and calculates their eGFR (estimated glomerular filtration rate) prior to contrast agent administration via a finger prick. Blood creatinine levels and eGFR are key clinical factors, allowing the clinician to assess patient renal function and eligibility for IV contrast administration. The test is designed to minimize the potential for CIN (Contrast Induced Nephropathy), which can include such serious conditions as renal impairment from iodine based contrast to NSF (Nephrogenic Systemic Fibrosis) from gadolinium based contrast.

For more information: www.acistmedical.com

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init